Fistein

    • FisteinFistein
      ·09:25
      $Bumitama Agri(P8Z.SI)$ 2.5 Target Price. Bumitama Agri's stock outlook looks promising, with analysts predicting a positive trend. The company's share price is expected to rise over the next 12 months, with an average price target of SGD$2.5 representing a 19% upside from the current price. *Key Highlights:* - *Revenue Growth*: Bumitama Agri is expected to achieve double-digit revenue growth, driven by healthy orders from biodiesel customers. - *Dividend Yield*: The company offers a dividend yield of 2.9%, with a history of increasing dividend payments. - *Analyst Ratings*: Bumitama Agri has a Strong Buy consensus rating, with analysts from Maybank Research, DBS Research, and UOB Kay Hian maintaining a Buy rating. *Price Targets:* - *Highest T
      9Comment
      Report
    • FisteinFistein
      ·09:04
      $PanUnited(P52.SI)$ 2 Target Price. *Growth Catalysts for Pan-United Corporation (P52.SI)* Pan-United is Singapore's largest ready-mixed concrete producer, and analysts see several drivers supporting growth into 2026-2027: 1). Singapore Construction Demand Surge - *Public sector pipeline*: New HDB developments, Cross Island Line, Tuas Mega Port, and institutional projects are expected to drive ∼55% of total construction demand. - *RMC volume growth*: Ready-mix concrete demand is projected to jump 34% from 13.4 million m³ in 2024 to 18 million m³ by 2027. - Analysts forecast EPS for Pan-United to grow 6-22% in FY26-FY27 on stronger offtake volume. *2. ESG & Low-Carbon Concrete Leadership* - Pan-United specializes in low-carbon concrete techno
      90Comment
      Report
    • FisteinFistein
      ·09-08 19:43
      $Silvercorp Metals Inc(SVM)$ 15 Target Price, due to global Silver output deficit --About SilverCorp Metals Inc (SVM)-- Silvercorp Metals Inc. (SVM) is a profitable silver-focused producer with low-cost underground mining operations in China, along with exploration and development assets globally. --Growth Catalysts for SilverCorp Metals Inc (SVM)-- 1). Ying Mining District Expansion & Upgrades: Silvercorp has completed the flotation line expansion at its flagship Ying Mining District in Henan Province, increasing processing capacity to 1,500 tonnes per day. Ongoing underground development and equipment upgrades aim to maintain high throughput and improve long-term operational efficiency. 2). Kuanping & Exploration Projects: Exploration and
      921
      Report
    • FisteinFistein
      ·09-08 10:58
      $IX Biopharma(42C.SI)$ 0.8 Target Price. --iX Biopharma Ltd(42C) Growth Catalysts-- Shift towards commercialisation of WaferiX subligual delivery of drugs could bump up revenue by as much as 250% in FY-2026, backed by planned capacity expansion. Out-licensing of the sublingual ketamine wafer, Wafermine, for Phase 3 development will be a major catalyst and expected to turn iX Biopharma profitable in long-term. Specialty pharmaceutical and nutraceutical drugs will benefit from the planned six-fold increase in production capacity to meet the expected surge in demand. Investment Merits Out-licensing world's first sublingual ketamine formula, Wafermine, for Phase 3 development is a near-term catalyst. Since the completion of its end-of-Phase 2 meetin
      5133
      Report
    • FisteinFistein
      ·09-07 14:54
      $IX Biopharma(42C.SI)$ 0.8 Target Price. --iX Biopharma Ltd(42C) Growth Catalysts-- Shift towards commercialisation of WaferiX subligual delivery of drugs could bump up revenue by as much as 250% in FY-2026, backed by planned capacity expansion. Out-licensing of the sublingual ketamine wafer, Wafermine, for Phase 3 development will be a major catalyst and expected to turn iX Biopharma profitable in long-term. Specialty pharmaceutical and nutraceutical drugs will benefit from the planned six-fold increase in production capacity to meet the expected surge in demand. Investment Merits Out-licensing world's first sublingual ketamine formula, Wafermine, for Phase 3 development is a near-term catalyst. Since the completion of its end-of-Phase 2 meeting with the US Food and Drugs Administration (
      2361
      Report
    • FisteinFistein
      ·09-07 09:11
      $IX Biopharma(42C.SI)$ 0.8 Target Price. --Ix Biopharama Medical Breakthrough-- iX Biopharma achieved a major medical and commercial breakthrough with Wafermine, its patented sublingual (under-the-tongue) ketamine wafer for non-opioid acute pain management. --The Core Technology-- WaferiXFast Absorption: Wafers dissolve sublingually in minutes, letting active ingredients enter the bloodstream directly and bypass the gut. High Bioavailability: Provides a needle-free, predictable alternative to intravenous infusions or standard oral pills. Drug Repurposing: Applies the delivery system to central nervous system agents and other urgent indications. --Key Pipeline & Commercial Milestones-- Backed by a US$40.95 million contract from the US Departm
      409Comment
      Report
    • FisteinFistein
      ·09-04
      $PanUnited(P52.SI)$ $ 2.50 Target Price. *Growth Catalysts for Pan-United Corporation (P52.SI)*   Pan-United is Singapore's largest ready-mixed concrete producer, and analysts see several drivers supporting growth into 2026-2027: 1). Singapore Construction Demand Surge - *Public sector pipeline*: New HDB developments, Cross Island Line, Tuas Mega Port, and institutional projects are expected to drive ∼55% of total construction demand. - *RMC volume growth*: Ready-mix concrete demand is projected to jump 34% from 13.4 million m³ in 2024 to 18 million m³ by 2027. - *Positive Analysts Forecast*:  EPS for Pan-United to grow 22% in FY26-FY27 on stronger offtake volume. -* ESG & Low-Carbon Concrete Leadership*: Pan-United specialize
      3341
      Report
    • FisteinFistein
      ·09-04
      $Silvercorp Metals Inc(SVM)$ 15 Target Price, due to global Silver output deficit  --About SilverCorp Metals Inc (SVM)-- Silvercorp Metals Inc. (SVM) is a profitable silver-focused producer with low-cost underground mining operations in China, along with exploration and development assets globally. --Growth Catalysts for SilverCorp Metals Inc (SVM)-- 1). Ying Mining District Expansion & Upgrades: Silvercorp has completed the flotation line expansion at its flagship Ying Mining District in Henan Province, increasing processing capacity to 1,500 tonnes per day. Ongoing underground development and equipment upgrades aim to maintain high throughput and improve long-term operational efficiency. 2). Kuanping & Exploration Projects: Explorati
      5361
      Report
    • FisteinFistein
      ·09-03
      $Silvercorp Metals Inc(SVM)$ $15 Target Price on global physical Silver demand deficit. Growth Catalysts for SVM Silvercorp Metals (SVM) has made some exciting recent discoveries. At their LMW underground mine in China's Ying Mining District, they've found high-grade silver, gold, and copper mineralization. Some notable intercepts include: - *2,705 g/t silver* over 18.02 meters in vein W18W - *34 g/t gold* and *4.45% copper* over 0.82 meters in vein LM28 - *4,738 g/t silver* over 1.80 meters in vein LM32E   These discoveries have expanded known mineralized zones and identified new vein structures with high-grade mineralization. The company is also advancing the El Domo Project in Ecuador, with construction expected to be completed by Q2-2026,
      4382
      Report
    • FisteinFistein
      ·09-02
      $CNMC Goldmine(5TP.SI)$ 2 Target Price   CNMC is a pure-play gold producer operating the Sokor gold field in Kelantan, Malaysia. --Growth Catalysts for CNMC Goldmine(5TP.SI)-- 1. Expanded Production Capacity   CIL Plant upgrade completed in April 2025: Daily processing capacity nearly doubled from 500 tonnes to 800 tonnes per day. Gold output from the CIL plant jumped 65% in 2H2025 vs 2H2024. CNMC Goldmine earnings growth came from "diversification into base metals production and the expansion of the gold processing capacity, not simply from rising gold prices. 2. Underground Development & Higher-Grade Ore Discovery  New underground facility under construction at Sokor. Two new vertical shafts budgeted at US$12M
      9241
      Report
       
       
       
       

      Most Discussed